Clinical Trial News Archive - April 2025
April 1, 2025
April 2, 2025
April 3, 2025
- AI Screening for Opioid Use Disorder Associated with Fewer Hospital Readmissions
- Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor VVD-159642 for Treatment of Advanced Solid Tumors
- Rilzabrutinib Granted Orphan Drug Designation in the US for Two Rare Diseases with No Approved Medicines
- BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
- Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
April 7, 2025
- Theravance Biopharma Presents Two New Ampreloxetine Analyses
- Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
April 10, 2025
- Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile in a Once Daily Pill
- Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis
- FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
April 11, 2025
April 14, 2025
- Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia
- Novo Nordisk Warns Consumers About Counterfeit Ozempic (semaglutide) Injection 1 mg in the US
- Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron
- Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
- Bristol Myers Squibb Provides Update on Camzyos Phase 3 ODYSSEY-HCM Trial
April 15, 2025
- Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
- Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
- Repurposing Blood Pressure Drug Reserpine May Prevent Vision Loss in Inherited Blinding Diseases
April 16, 2025
April 17, 2025
April 22, 2025
April 23, 2025
April 26, 2025
- Johnson & Johnson’s TAR-200 Monotherapy Demonstrates Highest Complete Response Rate with Sustained Clinical Benefits in Patients with Certain Types of Bladder Cancer
- Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBC
April 28, 2025
Clinical trial results archive
- 2025
- January, February, March, April
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.